Dynamic Technology Lab Private Ltd Invests $468,000 in Haemonetics Corporation $HAE

Key Points

• Dynamic Technology Lab Private Ltd has invested approximately $468,000 in Haemonetics Corporation, acquiring 7,360 shares in the 1st quarter, as reported in its recent SEC filing.
• Haemonetics reported earnings of $1.10 per share in its latest quarter, exceeding analysts' expectations and revealing a revenue of $321.39 million, despite a year-over-year decline of 4.4%.
• Institutional investors own about 99.67% of Haemonetics' stock, with notable increases in holdings from Citigroup and MetLife Investment Management, reflecting strong institutional interest.

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,360 shares of the medical instruments supplier's stock, valued at approximately $468,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Citigroup Inc. grew its position in Haemonetics by 87.3% in the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier's stock worth $39,755,000 after purchasing an additional 291,574 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Haemonetics by 448.0% in the 1st quarter. MetLife Investment Management LLC now owns 316,542 shares of the medical instruments supplier's stock worth $20,116,000 after buying an additional 258,776 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Haemonetics by 88.6% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 517,086 shares of the medical instruments supplier's stock worth $32,861,000 after acquiring an additional 242,956 shares during the period. Schwartz Investment Counsel Inc. increased its position in Haemonetics by 148.0% during the first quarter. Schwartz Investment Counsel Inc. now owns 374,500 shares of the medical instruments supplier's stock valued at $23,799,000 after acquiring an additional 223,500 shares during the last quarter. Finally, Boston Trust Walden Corp increased its position in Haemonetics by 22.1% during the first quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier's stock valued at $71,070,000 after acquiring an additional 202,609 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Price Performance

NYSE HAE opened at $53.61 on Thursday. Haemonetics Corporation has a 12 month low of $50.68 and a 12 month high of $94.99. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of 16.40, a PEG ratio of 1.00 and a beta of 0.39. The company's 50 day moving average is $64.73 and its two-hundred day moving average is $65.55. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company's revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HAE. Raymond James Financial cut Haemonetics from a "strong-buy" rating to an "outperform" rating and dropped their target price for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Robert W. Baird began coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Wednesday, July 9th. Finally, Barrington Research dropped their price target on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average target price of $82.50.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.